The global cholera vaccines market reached a value of US$ 4.36 million in 2021. Looking forward, the market is projected to reach a value of US$ 8.63 million by 2027, exhibiting a CAGR of 11.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cholera is an intestinal disease caused by bacterial infections that spread through contaminated food and water. It leads to severe diarrhea, dehydration, abdominal pain, fever, rapid heart rate, loss of skin elasticity, low blood pressure, muscle cramps, and dry mucous membranes, such as the inside of the mouth, throat, nose, and eyelids. It is presently a global threat to public health, which can be prevented through the vaccine. The cholera vaccine exposes a small dose of live cholera bacteria in the body that helps develop immunity against the disease. It can be given orally or injected intradermally or intramuscularly in the body.
The growing prevalence of cholera on account of poor hygiene and sanitation represents one of the major factors driving the market. In addition, there is a rise in the use of contaminated water for agriculture and olericulture across the globe. This, along with the increasing consumption of street and fast food due to the hectic lifestyles of individuals, is propelling the growth of the market. Moreover, there is a considerable rise in water pollution on account of sewage and factory wastes getting discharged into lakes and rivers. As a result, people are consuming contaminated seafood worldwide, which, in turn, is resulting in the spread of cholera. Additionally, rising awareness about cholera through initiatives of non-governmental organizations (NGOs), along with numerous immunization programs introduced by governments of several countries to reduce vaccine-preventable diseases, is positively influencing the market. Furthermore, key market players are extensively investing in research and development (R&D) activities to provide more efficient and cost-effective cholera vaccines, which is projected to propel the growth of the market.
This report provides an analysis of the key trends in each sub-segment of the global cholera vaccines market, along with forecasts at the global, regional and country level from 2022-2027. The report has categorized the market based on vaccine type, product and End-user.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Eubiologics Co. Ltd., Johnson & Johnson, Merck & Co. Inc, Pfizer Inc., PharmaChoice Canada Inc, Sanofi S.A., Takeda Pharmaceutical Company Limited and Valneva SE.
Cholera is an intestinal disease caused by bacterial infections that spread through contaminated food and water. It leads to severe diarrhea, dehydration, abdominal pain, fever, rapid heart rate, loss of skin elasticity, low blood pressure, muscle cramps, and dry mucous membranes, such as the inside of the mouth, throat, nose, and eyelids. It is presently a global threat to public health, which can be prevented through the vaccine. The cholera vaccine exposes a small dose of live cholera bacteria in the body that helps develop immunity against the disease. It can be given orally or injected intradermally or intramuscularly in the body.
Cholera Vaccines Market Trends
The growing prevalence of cholera on account of poor hygiene and sanitation represents one of the major factors driving the market. In addition, there is a rise in the use of contaminated water for agriculture and olericulture across the globe. This, along with the increasing consumption of street and fast food due to the hectic lifestyles of individuals, is propelling the growth of the market. Moreover, there is a considerable rise in water pollution on account of sewage and factory wastes getting discharged into lakes and rivers. As a result, people are consuming contaminated seafood worldwide, which, in turn, is resulting in the spread of cholera. Additionally, rising awareness about cholera through initiatives of non-governmental organizations (NGOs), along with numerous immunization programs introduced by governments of several countries to reduce vaccine-preventable diseases, is positively influencing the market. Furthermore, key market players are extensively investing in research and development (R&D) activities to provide more efficient and cost-effective cholera vaccines, which is projected to propel the growth of the market.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global cholera vaccines market, along with forecasts at the global, regional and country level from 2022-2027. The report has categorized the market based on vaccine type, product and End-user.
Breakup by Vaccine Type:
- Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- Killed Oral O1 and O139
Breakup by Product:
- Dukoral
- Shanchol
- Vaxchora
- Euvichol and Euvichol-Plus
- Others
Breakup by End-user:
- Hospitals and Clinics
- Research and Academic Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Eubiologics Co. Ltd., Johnson & Johnson, Merck & Co. Inc, Pfizer Inc., PharmaChoice Canada Inc, Sanofi S.A., Takeda Pharmaceutical Company Limited and Valneva SE.
Key Questions Answered in This Report
- How has the global cholera vaccines market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global cholera vaccines market?
- What are the key regional markets?
- What is the breakup of the market based on the vaccine type?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the End-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global cholera vaccines market and who are the key players?
- What is the degree of competition in the industry?
Frequently Asked Questions about the Global Cholera Vaccines Market
What is the estimated value of the Global Cholera Vaccines Market?
What is the growth rate of the Global Cholera Vaccines Market?
What is the forecasted size of the Global Cholera Vaccines Market?
Who are the key companies in the Global Cholera Vaccines Market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Cholera Vaccines Market
6 Market Breakup by Vaccine Type
7 Market Breakup by Product
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Astellas Pharma Inc.
- Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
- Emergent BioSolutions Inc.
- Eubiologics Co. Ltd.
- Johnson & Johnson
- Merck & Co. Inc
- Pfizer Inc.
- PharmaChoice Canada Inc
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Valneva SE
Methodology
LOADING...
